NASDAQ:TCDA - Tricida Stock Price, Forecast & News

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Tricida Inc (NASDAQ:TCDA) announced its quarterly earnings data on Thursday, November, 14th. The company reported ($0.89) EPS for the quarter, hitting the consensus estimate of ($0.89). View Tricida's Earnings History.

Tricida is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Tricida.

3 Wall Street analysts have issued 1-year target prices for Tricida's stock. Their forecasts range from $48.00 to $58.00. On average, they expect Tricida's stock price to reach $51.50 in the next twelve months. This suggests a possible upside of 23.8% from the stock's current price. View Analyst Price Targets for Tricida.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tricida.

News stories about TCDA stock have been trending somewhat negative on Monday, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Tricida earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Tricida.

Tricida saw a increase in short interest in November. As of November 15th, there was short interest totalling 3,590,000 shares, an increase of 5.9% from the October 31st total of 3,390,000 shares. Based on an average daily volume of 199,400 shares, the days-to-cover ratio is presently 18.0 days. Approximately 10.4% of the shares of the stock are short sold. View Tricida's Current Options Chain.

Some companies that are related to Tricida include Sarepta Therapeutics (SRPT), Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Catalent (CTLT), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), The Medicines (MDCO), Arrowhead Pharmaceuticals (ARWR), Horizon Therapeutics (HZNP), Reata Pharmaceuticals (RETA), Allakos (ALLK), Global Blood Therapeutics (GBT), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO) and FibroGen (FGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Global Blood Therapeutics (GBT), Madrigal Pharmaceuticals (MDGL), Exelixis (EXEL), Galmed Pharmaceuticals (GLMD), GW Pharmaceuticals PLC- (GWPH), Ocular Therapeutix (OCUL), SAGE Therapeutics (SAGE), Affimed (AFMD), Amarin (AMRN) and Arena Pharmaceuticals (ARNA).

(TCDA) raised $175 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

Tricida's stock is owned by many different of retail and institutional investors. Top institutional investors include Redmile Group LLC (4.19%), Great Point Partners LLC (1.18%), State Street Corp (1.01%), Massachusetts Financial Services Co. MA (0.64%), Point72 Asset Management L.P. (0.57%) and California Public Employees Retirement System (0.09%). Company insiders that own Tricida stock include Beek Jeroen B Van, Brian M Isern, Claire Lockey, Dawn Parsell Otto, Edward J Hejlek, Geoffrey M Parker, Gerrit Klaerner, Klaus R Dr Veitinger, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP, Steffen Pietzke and Wilhelm Stahl. View Institutional Ownership Trends for Tricida.

TCDA stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, Millennium Management LLC, Massachusetts Financial Services Co. MA and Rhumbline Advisers. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Claire Lockey, Dawn Parsell Otto, Gerrit Klaerner, Klaus R Dr Veitinger, Robert J Alpern, Sandra I Coufal, Sibling Capital Fund Ii-A LP and Wilhelm Stahl. View Insider Buying and Selling for Tricida.

TCDA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Redmile Group LLC, California Public Employees Retirement System, State Street Corp, Barclays PLC, Nisa Investment Advisors LLC, Tower Research Capital LLC TRC and Metropolitan Life Insurance Co NY. Company insiders that have bought Tricida stock in the last two years include Beek Jeroen B Van, Edward J Hejlek, Geoffrey M Parker, Longitude Capital Partners Ii,, Orbimed Advisors Llc, Sandra I Coufal and Steffen Pietzke. View Insider Buying and Selling for Tricida.

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TCDA stock can currently be purchased for approximately $41.60.

Tricida has a market capitalization of $2.06 billion. The company earns $-102,810,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis. Tricida employs 76 workers across the globe.View Additional Information About Tricida.

The official website for Tricida is http://www.tricida.com/.

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 415-429-7800 or via email at [email protected]